1-2 of 2
Keywords: Tremelimumab
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (2017) 93 (Suppl. 1): 147–159.
Published Online: 20 December 2017
... carcinoma (HCC). Results of combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab in HCC were presented at the 2017 annual meeting of the ASCO (American Society of Clinical Oncology). Response rates were 25% in all 40 patients and 40% in the 20 uninfected...